Shenzhen Hepalink Pharmaceutical Co Ltd Financial Flexibility Index
Shenzhen Hepalink Pharmaceutical Co Ltd financial flexibility index. Shenzhen Hepalink Pharmaceutical Co Ltd (002399) has a Financial Flexibility Index of 0.09x as of September 2025. Free cash flow of CN¥413.04 Million (operating CF CN¥399.43 Million minus capex CN¥13.60 Million) represents 0% of total liabilities (CN¥4.70 Billion). See Shenzhen Hepalink Pharmaceutical Co Ltd (002399) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Shenzhen Hepalink Pharmaceutical Co Ltd (2006–2025)
Financial flexibility index of Shenzhen Hepalink Pharmaceutical Co Ltd from 2006 to 2025. Historical Financial Flexibility Index trend for Shenzhen Hepalink Pharmaceutical Co Ltd across 20 annual periods. Check cash flow quality index of Shenzhen Hepalink Pharmaceutical Co Ltd to evaluate the quality of earnings relative to operating cash generation.
Shenzhen Hepalink Pharmaceutical Co Ltd Financial Flexibility Index by Year (2006–2025)
Shenzhen Hepalink Pharmaceutical Co Ltd financial flexibility index by year from 2006 to 2025. Year-by-year free cash flow to debt coverage for Shenzhen Hepalink Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see 002399 cash generation efficiency.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.40x | CN¥1.83 Billion | CN¥1.71 Billion | CN¥4.55 Billion | ▼ -13.6% |
| 2024 | 0.47x | CN¥2.40 Billion | CN¥2.19 Billion | CN¥5.14 Billion | ▲ +299.0% |
| 2023 | 0.12x | CN¥843.09 Million | CN¥398.22 Million | CN¥7.22 Billion | ▲ +283.9% |
| 2022 | -0.06x | CN¥-534.19 Million | CN¥-756.61 Million | CN¥8.41 Billion | ▼ -357.4% |
| 2021 | 0.02x | CN¥187.23 Million | CN¥-6.63 Million | CN¥7.58 Billion | ▼ -27.5% |
| 2020 | 0.03x | CN¥249.77 Million | CN¥37.28 Million | CN¥7.34 Billion | ▲ +96.7% |
| 2019 | 0.02x | CN¥134.47 Million | CN¥-227.60 Million | CN¥7.77 Billion | ▼ -89.3% |
| 2018 | 0.16x | CN¥1.20 Billion | CN¥667.87 Million | CN¥7.41 Billion | ▲ +428.5% |
| 2017 | 0.03x | CN¥169.01 Million | CN¥-407.12 Million | CN¥5.50 Billion | ▼ -79.0% |
| 2016 | 0.15x | CN¥705.61 Million | CN¥346.07 Million | CN¥4.83 Billion | ▼ -53.5% |
| 2015 | 0.31x | CN¥1.06 Billion | CN¥893.71 Million | CN¥3.38 Billion | ▼ -54.0% |
| 2014 | 0.68x | CN¥1.08 Billion | CN¥912.80 Million | CN¥1.58 Billion | ▼ -80.5% |
| 2013 | 3.51x | CN¥714.94 Million | CN¥420.97 Million | CN¥203.80 Million | ▲ +5.8% |
| 2012 | 3.32x | CN¥711.44 Million | CN¥473.89 Million | CN¥214.53 Million | ▼ -87.1% |
| 2011 | 25.67x | CN¥1.54 Billion | CN¥1.41 Billion | CN¥59.98 Million | ▲ +579.3% |
| 2010 | 3.78x | CN¥390.80 Million | CN¥354.86 Million | CN¥103.44 Million | ▲ +181.8% |
| 2009 | 1.34x | CN¥410.72 Million | CN¥355.81 Million | CN¥306.33 Million | ▲ +613.5% |
| 2008 | 0.19x | CN¥50.94 Million | CN¥40.13 Million | CN¥271.09 Million | ▼ -18.9% |
| 2007 | 0.23x | CN¥25.80 Million | CN¥13.85 Million | CN¥111.28 Million | ▼ -27.5% |
| 2006 | 0.32x | CN¥82.36 Million | CN¥71.66 Million | CN¥257.68 Million | — |